Latest AJCC Edition Staging System May Not Be As Effective in Differentiating Survival in Melanoma

An external validation of the American Joint Committee on Cancer (AJCC) 8th edition staging system found that the latest edition maintained a similar prognostic accuracy as its predecessor

BMS’ Opdivo cuts risk of melanoma recurrence

Bristol-Myers Squibb’s Opdivo, which is being investigated as adjuvant treatment after surgery for stage IIIb/c or IV melanoma patients at high risk of recurrence, may significantly cut the risk of patients’ cancer returning at 24 months versus Yervoy.

Nivolumab More Effective Than Ipilimumab in Resected High-Risk Melanoma

Extended follow-up from the CheckMate 238 trial confirmed the superior efficacy of nivolumab compared with ipilimumab in patients with stage III and IV resected melanoma.

T-cell redirection therapy shows durable response for metastatic uveal melanoma

Immunocore Limited presented data from the IMCgp100-102 trial at the American Society of Clinical Oncology meeting that showed a durable response and strong overall survival rate in patients with metastatic uveal melanoma.

Cancer in the News

Feature Articles

Pembrolizumab Is Effective in Unresectable Melanoma, at 4-Year Follow-Up

After 4 years of follow-up, pembrolizumab demonstrated durable antitumor activity and improved outcomes over ipilimumab in advanced melanoma, according to results from the KEYNOTE-006 trial.

Read the full story

Posted in Melanoma In The News, Health Professionals

What Surveillance Testing Should Be Done After Melanoma Diagnosis? What is the background for this study? What are the main findings?

Read the full story

Posted in Melanoma In The News, Information

T-VEC Immunotherapy Shows Promising Early Activity in Melanoma

Twelve weeks of neoadjuvant exposure to talimogene laherparepvec (T-VEC) was associated with few high-grade toxicities and a promising pathological complete tumor-response (pCR) rate

Read the full story

Posted in Melanoma In The News, Clinical Trials

Encorafenib plus binimetinib prolongs OS for advanced BRAF-mutated melanoma

Combination therapy with encorafenib plus binimetinib significantly improved OS compared with vemurafenib or encorafenib alone for patients with advanced BRAF-mutated melanoma, according to phase 3 results from the COLUMBUS trial presented at ASCO Annual Meeting.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories